One of these two treats fat. The other treats fat and muscle, using two different energies under two separate FDA clearances. truSculpt iD is monopolar radiofrequency and nothing else. It heats tissue. EmSculpt NEO pairs two things in one applicator. A pulsed magnetic field forces muscle to contract, and radiofrequency heats the tissue at the same moment.
truSculpt iD's fat wording covers the abdomen only. The cleared indication gives the 2 MHz setting on the 40 cm2 handpiece "reduction in circumference of the abdomen and non-invasive lipolysis (breakdown of fat) of the abdomen" (Cutera, K221407, 13 July 2022). There is no thigh, flank, arm or buttock fat wording in it, and no muscle claim of any kind. The rest of that same clearance is medical heating wording, for pain, muscle spasm and local circulation. A separate massage attachment carries "a temporary reduction in the appearance of cellulite."
EmSculpt NEO's wording is split across two different regulations. That is where most comparisons go wrong. The fat and circumference wording sits on radiofrequency filings. Abdomen came in December 2019, thighs in January 2021, upper arms in January 2022, and flanks in September 2023. The upper arm wording is limited to skin types II and III and a body mass index of 30 or under. The flank wording covers skin types I to IV. The muscle wording covers abdomen, buttocks, thighs, calves and arms. It sits on separate electromagnetic filings that carry no fat claim at all.
Cutera advertises "an average of 24% fat reduction" for truSculpt iD. That figure could not be traced to a named published study. There is no author, year, sample size or measurement method attached to it. The published truSculpt evidence is small. It is an ultrasound study of a single treatment session in 12 people, plus a 14-person study of the lower face.
Both devices are FDA cleared, not FDA approved. A 510(k) clearance is a finding that a device is much the same as one already on the market. It is not a finding that the device works, or works well, or is worth the money.
Monopolar RF, delivered through a 40 cm2 hands-free handpiece or smaller handpieces. There is no muscle stimulation in it. Cutera's muscle device is a different product, truSculpt flex, which uses electrodes.
Two energies in one applicator. A pulsed magnetic field switches on motor neurons, and bipolar radiofrequency supplies the heat.
In the published truSculpt study, skin temperature ran 44 to 45 degrees Celsius, with the temperature under the skin above 45.
FDA's performance testing on the fat filing records a therapy temperature of 40 to 43 degrees Celsius, held for the rest of the session. On the muscle filing, the radiofrequency is described only as warming the applicator surface to below 40 degrees for comfort. Same brand, two filings, two different roles for the same energy.
K221407, 13 July 2022. The same wording appears on the 2018 filing K180709. Note that a later truSculpt iD clearance, K223110, carries no body mass index limit in its indications.
Fat wording by area, in the filings whose device descriptions match it: abdomen (2019), thighs (2021), upper arms (2022, skin types II-III and BMI 30 or under), flanks (2023, skin types I-IV). Muscle wording: abdomen, buttocks, thighs, calves, arms. Note there is no fat clearance for buttocks or calves.
Anything else falls outside the cleared fat wording. That is legal, because clinicians may use a cleared device off its clearance. But it means the evidence FDA reviewed does not cover it.
BTL's website also markets "back" and "legs" as treatment zones. Those are not in the cleared area list.
It is a single-purpose heat device, and the shorter treatment of the two.
The muscle side is the part truSculpt iD cannot do at all.
Clinics describe it as a hot stone massage. There is no forced muscle contraction and no delayed soreness.
Intensity is ramped up to the highest level you can bear. In the FDA summary of the abdominal fat study, 11 of 42 subjects reported muscle soreness afterwards, and 92.9% reported none to minimal discomfort during treatment.
The 12-person ultrasound study reported no downtime requirement.
Across the published EmSculpt and NEO studies, most report no side effects at all. FDA's post-market database holds one reported skin burn with EmSculpt NEO (2022) and one reported hard lump on the quadriceps (2023). That database is voluntary and has no denominator, so those counts cannot be turned into a rate.
That is manufacturer and clinic guidance, not a labelled instruction.
BTL does not publish its instructions for use, so there is no labelled session count to quote. The pivotal abdominal study used three sessions. The thigh study used four. BTL's website says four.
An ultrasound study of one treatment in 12 people, assessed at 8 and 12 weeks. And a 14-person study of monopolar RF on the lower face. The advertised 24% average fat reduction could not be tied to either.
A 2025 systematic review of NEO found seven studies. Mean fat thickness fell 8.0 mm and mean muscle thickness rose 5.5 mm. The review stated that all seven were written by BTL medical advisors. There is one randomised sham-controlled trial, n=72, and its authors are also BTL-linked.
truSculpt iD's abdominal wording and EmSculpt NEO's abdominal fat wording are close cousins. Both sit under the same FDA regulation for devices that heat tissue to break down fat. Both say "non-invasive lipolysis" and "reduction in circumference." Where they part company is muscle. truSculpt iD holds no muscle-toning indication anywhere. Cutera's muscle device is truSculpt flex, a separate machine that uses sticky electrodes rather than heat. It is cleared for abdomen, buttocks and thighs only.
So if you have been quoted for truSculpt iD and EmSculpt NEO as two versions of the same treatment, they are not. One is a heat treatment for abdominal fat. The other is a heat treatment for fat in four areas that runs a muscle treatment in five areas at the same time.
Percentage fat-reduction figures in this field almost always mean one thing. They mean a percentage of the thickness of the fat layer under the skin, measured at one point, on one axis, usually by ultrasound or a single MRI slice. They are not a percentage of your body fat. They are not a percentage of the bulge's volume. They are not a percentage of your weight.
For scale, the pooled published numbers across this whole device class sit between two and eight millimetres of fat-layer thickness. Cutera's 24% figure could not be tied to a named study. So there is no sample size, no measurement method and no follow-up interval attached to it. Treat an unattributed percentage as a marketing figure until someone can name the paper.
The most useful independent scrutiny of the EmSculpt NEO literature comes from Eric Swanson, a plastic surgeon who declares no industry ties. His 2025 review of seven NEO studies reached three conclusions. Measured changes were "likely within the margin of error and of questionable clinical relevance." Photographs were often not standardised. And MRI scans were affected by differing levels of the axial slice. He also notes that he is a practising liposuction surgeon, and his reviews consistently conclude that liposuction remains the gold standard. That is a structural interest worth knowing about while you read him.
On the truSculpt side there is simply less to scrutinise. Two small studies, neither randomised, neither sham-controlled.
The honest split is this. If the only thing you want is less fat over the abdomen, and you would rather not feel your muscles firing for half an hour, truSculpt iD does that job in one or two short appointments. If you also want the abdominal muscle worked on, truSculpt iD cannot do it. EmSculpt NEO is the machine of the two that holds that wording.
Neither is a weight-loss treatment. FDA states this plainly for the whole category. Non-invasive body contouring "will not result in weight loss or contribute to the health benefits associated with weight loss."
Tell your provider in advance about any pacemaker, implanted defibrillator, neurostimulator, drug pump or metal implant near the treatment area: Both of these are energy devices, and both device types exclude implants. Radiofrequency is excluded because it heats metal. Magnetic stimulation is excluded because it induces current in it.
Say so if you have a hernia in or near the area to be treated, including a repaired one: FDA names hernia as a serious risk across the non-invasive body-contouring class. It appears in the published safety information for devices on both sides of this comparison.
Ask which clearance the treatment you are being sold sits under, and for which area: For truSculpt iD, the fat wording applies to the abdomen. For EmSculpt NEO, ask whether you are being treated for fat, for muscle, or both, and in which area. The two claims cover different maps of the body.
Ask what happens if you buy a package and stop partway: Neither device has a published maintenance protocol. The intervals clinics quote are convention.
Fever or chills after treatment
Redness around a treated area that is visibly spreading hour by hour
Pus or discharge from treated skin
A blister or open wound that appeared during or straight after a radiofrequency treatment and is getting worse
These are signs of a burn or a spreading infection, and they need care the same day.
Pain or tenderness in a treated area is increasing after day three instead of settling
A firm lump appears in a treated area and does not settle over a few weeks
The treated skin darkens, blisters or crusts
An area starts to look dented or uneven compared with the other side
Muscle soreness after a magnetic stimulation session is bad enough to stop you moving normally, or lasts more than a few days
You feel numbness or altered sensation in the treated area that is not improving